Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Rhone-Poulenc Rorer acquires 37% of Applied Immune Sciences

Executive Summary

Applied Immune Sciences gets a global development and marketing partner and Rhone-Poulenc Rorer buys into a research program in gene and cell therapy as RPR acquired 37% of AIS for $113 million with the option of acquiring up to 60%.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Acquisition
    • Includes Earnout
    • Partial Acquisition
    • Payment Includes Cash
    • Payment Includes Stock

Related Companies